This Organaization has been founded to succeed the will of late Dr. Shuhei Ogita, who was a pediatric surgeon and the great developer of a new OK-432 therapy for lymphatic malformations (cystic hygroma, lymphangioma). The mission of the corporation is to assist the patients of all over the world.